- GSK halted camlipixant for refractory chronic cough after mixed Phase 3 results. Shares fell up to 4.5%. Company redirects focus to other programs, including oncology, for its 2031 growth plan.
- GSK reported Phase 3b data: a single booster restores immune protection in 10–20-year-olds; full results to be presented at the International Pathogenic Neisseria Conference in September.
TradingView
Key facts: GSK halts camlipixant; booster restores immunity in 10–20s
- Sources
- TradingView
- Markets
- Stocks
- Active symbols
- LSE:GSK
- Language
- English
GSK halted camlipixant for refractory chronic cough after mixed Phase 3 results. Shares fell up to 4.5%. Company redirects focus to other programs, including oncology, for its 2031